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ments and supports the feasibility of this approach. CONCLUSIONS: This novel
design seeks to address the bias inherent in observational research through the
imposition of randomization. By separating data collection into a preliminary
phase collecting only variables needed for treatment identification and random-
ization and a separate full review of only these randomly-selected patient records,
chart abstraction burden is minimized. Furthermore, the use of propensity score
matching to create two matched cohorts for comparison allows greater control of
potential confounding in analyses of treatment effect.
SB4
A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF
DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL
STUDIES
Kiri VA
PAREXEL International, Uxbridge, London, UK
OBJECTIVES: There are many examples in health outcomes research where inad-
equate control for comorbidity influence has resulted in effect estimates con-
founded by disease severity. Selection bias is a common feature of data from rou-
tine healthcare settingwhere the decision to give a particular drug to a patientwith
a given disease is generally based on patient characteristics, including disease
condition. Thus, failure to properly control for the bias could result in false associ-
ations. Propensity scores methodology is commonly used despite its limitations
because of its potential for minimising the association between exposure and con-
founding factors. We describe a methodology for assessing drug effect in longitu-
dinal data that minimises confounding by disease severity generally associated
with observational studies. METHODS: For a particular outcome of interest, we
obtain the profiles of rates ratios from two sets of matched cohorts. In set A, pa-
tients with disease X are compared with others free of X in the periods prior to and
post diagnosis of X. In set B which involves only patients with disease X, those
exposed to treatment Y are compared with those unexposed to the drug in the
periods prior to and post exposure. The two sets of profiles are then assessed using
simple regression over the respective periods. In effect, we attempt to disentangle
the disease and treatment effects. Data from the UK GPRD are used to assess
possible association between a particular outcome and treatment in COPD
RESULTS: We found evidence of association between the outcome and COPD but
none for the drug. CONCLUSIONS: The profile approach utilizes the data collected
over the disease natural history and exposure history to assess the relationships
between the outcome and both the disease and treatment. This is a key strength
often ignored when results are reported as point estimates. By design, it also mi-
nimises the effect of selection bias.
PODIUM SESSION II:
RESEARCH ON METHODS: COST-EFFECTIVENESS ANALYSIS
CE1
COST-EFFECTIVENESS SENSITIVITY ANALYSIS METHODS: A COMPARISON OF
ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE
OF PARTIAL PERFECT INFORMATION
Campbell J1, McQueen RB1, Libby A1, Briggs A2
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OBJECTIVES: Advanced sensitivity methods including value of information were
developed to quantify overall decision uncertainty and to assess the cost-effective-
ness of additional research that would reduce that uncertainty. Our objective was
to compare the information gained by utilizing three alternative sensitivity meth-
ods with increasing complexity: a simple one-way sensitivity analysis; probabilis-
tic analysis of covariance (ANCOVA); and expected value of partial perfect infor-
mation (EVPPI) of input parameters. METHODS: We replicated and expanded a
published HIV/AIDS cost-effectiveness Markov model (zidovudine vs. zidovudine
plus lamivudine in the UK) using TreeAge®. Health states included three HIV/AIDS
states and death. Our outcome of interest was the incremental net monetary ben-
efit (INMB) assuming awillingness-to-pay of £20,000/QALY.We generated one-way
and probabilistic sensitivity analyses of the INMB using published input parameter
uncertainties. One-way sensitivity analysis identified the 10 most influential pa-
rameters. A total of 10,000 Monte Carlo draws were used to estimate the ANCOVA
results from the same ten parameters. EVPPI for each of the same ten parameters
was estimated specifying 1000 inner and 1000 outerMonte Carlo draws.We ranked
the parameters based on their influence on variation for each sensitivity method
and compared themusing Spearman’s rank correlation. RESULTS:Mean INMBwas
£9694 in favor of combination therapy. The two most influential inputs were the
same across all methods, contributed 78% of variation in outcome (ANCOVA), and
were the only inputs with non-zero EVPPI values. The rank order for the top ten
inputs from all methods was similar (correlation0.99 for one-way vs. ANCOVA,
0.70 for one-way vs. EVPPI and 0.70 for ANCOVA vs. EVPPI, all p-values  0.05).
CONCLUSIONS: The correlation was significant between one-way and more ad-
vanced sensitivity analyses. Although each method provides unique information,
the additional resources needed to generate advanced analyses should beweighed,
especially when the outcome decision uncertainty and therefore value of informa-
tion is low.
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A NOVEL WAY OF ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL
TRIALS WITH MISSING DATA: A SIMULATION STUDY
Gagnon DD1, Engelhart L2
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OBJECTIVES: In a simulated dataset, evaluate incremental cost-effectiveness ratios
(ICERs) adjusted for covariates and missing data using three different regression
models. The regression parameter of interest is the incremental net monetary
benefit (INMB). Models are ANCOVA, mixed effects (ME), and joint mixed effects
and log time-to-dropout (joint ME), a selectionmodel.METHODS: Traditional cost-
effectiveness analysis (CEA) uses the incremental cost-effectiveness ratio (ICER), a
measurewith statistical issues and limitationswithmissing data. Regression anal-
ysis can estimate incremental net monetary benefit (INMB) and avoid these statis-
tical issues while adjusting for covariates as well as missing data. The cost-effec-
tiveness acceptability curve (CEAC) generated from a family of these regressions
can identify an ICER adjusted for the factors included in the INMB regressions (the
ICER is the point on the CEAC where the probability of being cost-effective is 50%).
Data were simulated to include missing at random (MAR) and missing not at ran-
dom (MNAR). Simulated treatment effect provided a “true” INMB for model evalu-
ations that included bias (absolute difference from “true”), precision (ratio of vari-
ances), and CEACs with willingness-to-pay () values from $0 to $100K. RESULTS:
TheANCOVA andMEmodels produced the least biased estimates. At  $50K, bias
was $1.3K, $1.4K, and 2.3K, and precision was 1.27, 0.90, and 1.24 for ME, ANCOVA,
and joint ME, respectively. The joint ME model performed best when missingness
was high. CONCLUSIONS: Once the CEACs had been generated, deriving ICERs
adjusted for covariates and missing data from those CEACs based upon INMB re-
gressions proved easy and feasible. The models used in this simulation analysis
performeddifferently under alternativemissingness conditions andwere sensitive
to nonresponsemechanisms. All estimateswere poorwhenmissingnesswas high;
suggesting prevention of missing data should be a goal of research.
CE3
COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ASSESSMENT: A
GRAPHICAL WAY TO COMBINE THE TWO FOR THE AID OF DECISION-MAKERS
Paulden M, Pham B
University of Toronto, Toronto, ON, Canada
OBJECTIVES: Cost-effectiveness analysis (CEA) has traditionally been seen as a
means of satisfying a specific and explicit social objective subject to a fixed budget
constraint. As a result, existing CEAmethods largely ignore budget impact consid-
erations in health systems where budgets are not fixed. In particular, none of the
traditional methods of presenting results (such as the cost-effectiveness plane,
ICER tables and CEAC graphs) can be used to summarize the results of a CEA and
budget impact assessment simultaneously. Our objective was to develop such a
method in a manner which is meaningful to decision makers. METHODS: We
present a novel way of combining cost-effectiveness and budget impact consider-
ations into a single graph. To do this, we disaggregate the incremental costs of the
new technology into those which fall on the health budget and displace other
technologies (resulting in forgone health) and those which lead to an expansion of
the health budget (resulting in a net budget impact). The incremental health ben-
efit of the technology and any forgone health are combined to give the net health
benefit of the technology,which is plotted against the net budget impact. RESULTS:
Our method clearly reveals the trade-off between the cost-effectiveness and
budget impact of the technology in question. This trade-off is simultaneously re-
vealed across a range of plausible values of the cost-effectiveness threshold.
CONCLUSIONS: Decision makers who are concerned with both the cost-effective-
ness and budget impact of new technologies have tended to consider each of these
separately, with the inherent trade-off between the two blurred in the process. Our
proposed method makes this trade-off explicit and does so across a range of
threshold values, enabling analysts to provide meaningful information to decision
makers while respecting decision makers’ authority in determining the appropri-
ate threshold to use.
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OBJECTIVES: To compare the differences in the methods used to estimate the
cost-effectiveness of vaccination programs using the clinical outcomes from dy-
namic transmission models. METHODS: A targeted electronic literature search of
title words in the PubMed databases was performed to identify studies published
since 2000 that included a description of themethods and presentation of results of
cost-effectiveness analysis of vaccination programs based on data from dynamic
transmission models for any infectious disease. Further studies were identified in
the bibliographies of the initial set of papers.RESULTS: Informationwas abstracted
from 29 papers presenting cost-effectiveness analyses of vaccination programs for
influenza, HPV, varicella virus, pertussis, meningococcal meningitis, rotavirus, H.
pylori, and hepatitis A. Both cohort and population-based estimates of cost-effec-
tiveness were presented. The population-based estimates had variable time hori-
zons from 1 year for influenza or pertussis (the steady state year) up to 100 years for
HPV, varicella, and meningococcal vaccination. All cohort analyses used a lifetime
time horizon. Four method types for the estimation and presentation of a cost-
effectiveness ratio were identified: 1) average population values (costs and bene-
fits) over a long time horizon assuming a continuing vaccination program (20 pa-
pers) 2) average population values over a long time horizon assuming a limited
duration vaccination program (1 paper) 3) population values for the steady-state
year only (1 paper) and 4) cohort values with a lifetime horizon (7 papers).
CONCLUSIONS: The variability of the estimation framework (population or cohort)
and time horizon used aswell as the variability in other input parameters observed
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in the review illustrate the problems that may be encountered in comparing cost-
effectiveness estimates of different vaccination programs among themselves as
well as with other prevention or treatment interventions.
PODIUM SESSION II:
RESEARCH ON METHODS: DATABASE ANALYSIS
DS1
INTEGRATING DATA SOURCES TO CONDUCT COMPREHENSIVE ONCOLOGY
BASED OUTCOMES RESEARCH
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OBJECTIVES: Individual data sources contain non-integrated data components
needed to assess outcomes, resource use, and costs in cancer patients. This work
describes methodology to integrate disparate electronic data sources in chronic
myelogenous leukemia (CML) patients with a common identifier (CI).METHODS: A
CML Patient cohort from the Huntsman Cancer Institute was created by extracting
information across theUtahCancer Registry; theUtah PopulationDatabase (UPDB);
and the Enterprise Data Warehouse, including Cerner inpatient and EPIC ambula-
tory care clinic data. Medication use was from inpatient medication orders. A
unique patient index identifier linked disparate records. RESULTS: A total of 602
patients were identified by ICD-9 diagnosis code for CML (250.1, 205.10-12) from
1995 through 2009,median age 51, 42.6% female. Of these 598 (99.3%) were linked
to the UPDB and 245 had a state death certificate. Charlson Comorbidity Index (CCI)
analysis (/ 90 days) identified 232 (38.5%) subjects with a score of zero, 199
(33.1%) with 1-3, 99 (16.4%) with 4-6, 47 (7.8%) with 7-9 and 25 (4.2%) with a score of
10-17 (median2,mean 2.6, and SD 3.1). Inpatient admission datawas available
for 380 (63.1%) patients, with a total of 267 CML related drug orders. Procedures
were observed for 531 (88.2%) patients. Lab results were available for 564 (93.7%)
subjects. Of those, BCR/ABL biomarker results were available for 210 (37.2% of all
lab results) patients. CONCLUSIONS: Integrating data across different data sources
in an academic health care center with a National Comprehensive Cancer Network
hospital can provide comprehensive health care data. This methodology may in-
fluence the evolution of electronic health records, as a data resource tool for out-
comes data, resource use and cost utilization across complex disease states such as
CML. Future research will expand on drug data sourcing and evaluate the medical
record notes to evaluate CML specific outcomes.
DS2
A VALIDATION STUDY OF ALGORITHMS FOR IDENTIFYING METASTATIC
BREAST, LUNG, OR COLORECTAL CANCER IN ADMINISTRATIVE CLAIMS DATA
Whyte JL1, Engel-Nitz NM2, Teitelbaum A2, Gomez Rey G2, Kallich J1
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OBJECTIVES: In cancer research using claims data, identifying metastases is often
essential yet difficult. The objective of this study was to examine the validity of
algorithms identifying metastatic breast (BC), lung (LC), or colorectal (CRC) cancer
in healthcare claims data. METHODS: A proprietary clinical cancer database con-
taining physician-reported clinical data on patients with BC, LC, or CRC between
January 1, 2007 and March 31, 2010, was linked to claims data. Inclusion required
health plan enrollment  3 months prior to the initial clinical cancer diagnosis
date. Un-validated claims algorithms from previous research were identified. A
generic metastatic algorithm with all metastatic ICD-9 codes and tumor-specific
variations of the algorithm were assessed for validity. The algorithms’ validity
versus the clinically reported metastases was tested using sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV). RESULTS: Of
14,480 patients in the database, 4631 BC (mean age 53.6 yr), 2449 LC (mean age 62.9
yr), and 2058 CRC patients (mean age 58.3 yr) met inclusion criteria. Metastases at
diagnosis were recorded in 8.0% (371) of BC, 49.2% (1204) of LC, and 25.7% (528) of
CRC patients. The tumor specific algorithm for identifyingmetastatic BC had 53.2%
sensitivity and 98.6% specificity; PPV and NPVwere 77.6 and 95.8. The lung-specific
algorithm had 55.2% sensitivity and 85.3% specificity; PPV and NPV were 81.0 and
62.6. Similarly, the CRC-specific algorithm had 59.4% sensitivity, 89.8% specificity,
with PPV 72.9 and NPV 82.7. The generic algorithm had lower specificity and higher
sensitivity for all 3 cancers and a significantly lower PPV for breast cancer.
CONCLUSIONS: Specificity, but not sensitivity, was high for all tumor-specific al-
gorithms. Although not tested, better sensitivity might be gained by including
chemotherapy in the algorithms for some tumor types.
DS3
AVAILABILITY OF LABORATORY RESULTS DATA IN A CLAIMS DATABASE IN
THE UNITED STATES
Horne LN, Ming EE, Doyle c
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OBJECTIVES: To describe the frequency of available laboratory results data in a
commercial healthcare database, among patients who are being treated for diabe-
tes or dyslipidemia and who have have at least one documented laboratory result
for a hemoglobin a1c (HbA1c) or lipid test. METHODS: The source population was
adults continuously enrolled in a large U.S. health plan during 2009 with at least
one CPT code for a HbA1c or lipid test. Laboratory results data were considered
available if LOINC codes or free text identified a result recorded within / 3 days
of the CPT claim date. The final study cohort included only patients with at least
one result available. We calculated the 1-year person-level percent of the number
of tests ordered in 2009 that had results available. Results for each test were strat-
ified by whether the patient received an antidiabetic or antidyslipidemia drug dur-
ing the same year. RESULTS: Overall, a result was available for 41% of HbA1c tests
and 42% of lipid tests. Persons with at least one prescription claim for an antidia-
betic or antidyslipidemia drug had more frequent tests recorded during the study
period (HbA1c: mean 4.5 with drug, 2.0 without drug; Lipid: mean 3.9 with drug, 2.0
without drug). However, results were less likely to be consistently available among
treated patients: 44% of those treated (among whom 70% of tests had results), and
39% of those not treated (among whom 83% of tests had results) had any results
available. CONCLUSIONS: While laboratory data may enhance studies conducted
in administrative claims databases, results may be inconsistently available. In this
study, among treated patients, 44% had any laboratory results recorded, for whom
results were missing approximately 30% of the time. An evaluation of the com-
pleteness of laboratory data prior to any study is feasible andmay help understand
any potential bias.
DS4
BURDEN OF PROOF. . .PROOF OF PRINCIPLE: REPLICATION QUANTIFICATION,
REPLICATION AND VALIDATION. . . STANDARDS OF EVIDENCE IN OUTCOMES
RESEARCH SURROGATE ENDPOINTS FOR ALL-CAUSE MORTALITY
Simons WR
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OBJECTIVES: To demonstrate replication of the quantification of relationships be-
tween surrogates and endpoints as well as reconciliation with previous epidemio-
logical studies; original studies for heart rate as a surrogatefor all-cause mortality,
painmanagement and gastrointestinal adverse events, and treatment for diabetes
and HbA1c and HbA1c and complications. METHODS: For heart rate, three epide-
miological studies from three countries using aWeibull survival analysis and Gen-
eralized Estimating Equations were used; namely, the Coronary Artery Surgery
Study (CASS), the Copenhagen City Heart Study (CCHS) and the General Practitio-
ner Research Network (GPRN). These equations reproduced a meta-regression and
meta-analysis of all available placebo-controlled clinical trials with heart rate as a
prognostic factor for all-cause mortality. For pain, data consisted of 2005 Health
Care Utilization Project (HCUP) and Premier. Logistic regressions were used to ob-
tain evaluate and compare odds-ratios. In diabetes, Generalized Estimating Equa-
tions (GEE) allowing serially correlated behavior with repeated HbA1c reading at
variable frequencies and durations between theirmeasurement.RESULTS:Heart is
consistently prognostic for all-cause mortality. Moreover, its quantification is con-
sistent, 0.00694 (P0.001) in CASS and 0.00683 (P0.001) in CCHS (1981-1983) and
0.00717 in CCHS (1991-1993)with theWeibull.With theGEE, the coefficient is 0.0268
(P0.006) in GPRN, 0.0249 (P0.008) in the meta-regression of controlled clinical
trials, and 0.01595 in the GEE with CCHS data. All three equations reproduced the
published clinical trials with odd-ratios within 1/100ths.Conditional odds-ratios
were replicated in measure between the two datasets for fecal impaction, post-
operative illeus, other bowel obstruction, vomiting and abdominal pain. The dia-
betic equations were replicated exactly in 3 countries, treatment and HbA1c and
complications with coefficients within 1/100th in patients with newly diagnosed
T2DM. CONCLUSIONS: These are three studies where the quantification of the
relationship between a surrogate and and endpoint have beed replicated with
precision and subsequently applied to clinical trials.
PODIUM SESSION II:
DRUG USE AND PATIENT SAFETY
DU1
COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED
WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
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OBJECTIVES: This study compared the risk of developing substance use disorder in
children with Attention-Deficit/Hyperactivity Disorder (ADHD) utilizing stimulant
and atomoxetine. METHODS: This study involved retrospective, propensity score
matched cohort assessing the risk of developing substance use disorder among
stimulant and atomoxetine users with ADHD using the IMS LifeLink Health Plan
ClaimsDatabase. Adolescents between 12 and 18 years of age starting on stimulant
or atomoxetine therapy from July 1, 2004 to December 31, 2005were included in the
study sample. Substance use disorder was classified into (i) tobacco use (ICD-9-CM
code- 305.1); (ii) drug abuse (ICD-9-CM codes- 305.2-305.9, 304.x, 292.x, 304.00-
304.03, 304.70-304.73); and (iii) alcohol abuse (ICD-9-CM codes- 265.2, 303.x, 305.0,
357.5, 425.5, 291.0-291.5, 291.9, 571.0, 571.2, 571.3, 535.3, and 790.3). Patients with
stimulant and atomoxetine were matched on propensity scores calculated on the
basis of baseline characteristics. Conditional logistic model was developed using
the STRATA option to account for the matched pair design to assess the risk of
substance use disorder development. Persistencymeasured as duration of therapy
was included as a covariate in the final model along with other covariates which
were significant after matching. RESULTS: The propensity score matched cohort
consisted of 2,030 adolescents with ADHD in both the stimulant and atomoxetine
user groups (total of 4,060 adolescents). Conditional logistic regression analysis did
not show any statistically significant difference between stimulant or atomoxetine
use and the risk of substance use development (Odds Ratio [OR]- 0.86; 95% CI-
0.29-2.50). Age was the only covariate that was significantly associated with the
substance use disorder (OR-3.55; 95% CI-1.25-10.13). CONCLUSIONS: Utilization of
stimulant was not significantly associated with higher risk of substance use disor-
der compared to atomoxetine in adolescents. More research is needed to evaluate
the long-term effects of use of medications in ADHD.
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